Literature DB >> 15066738

A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization.

M S Dryden1, S Dailly, M Crouch.   

Abstract

Two topical MRSA eradication regimes were compared in hospital patients: a standard treatment included mupirocin 2% nasal ointment, chlorhexidine gluconate 4% soap, silver sulfadiazine 1% cream versus a tea tree oil regimen, which included tea tree 10% cream, tea tree 5% body wash, both given for five days. One hundred and fourteen patients received standard treatment and 56 (49%) were cleared of MRSA carriage. One hundred and ten received tea tree oil regimen and 46 (41%) were cleared. There was no significant difference between treatment regimens (Fisher's exact test; P = 0.0286). Mupirocin was significantly more effective at clearing nasal carriage (78%) than tea tree cream (47%; P = 0.0001) but tea tree treatment was more effective than chlorhexidine or silver sulfadiazine at clearing superficial skin sites and skin lesions. The tea tree preparations were effective, safe and well tolerated and could be considered in regimens for eradication of MRSA carriage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066738     DOI: 10.1016/j.jhin.2004.01.008

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  29 in total

Review 1.  Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties.

Authors:  C F Carson; K A Hammer; T V Riley
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Uncontrolled, open-label, pilot study of tea tree (Melaleuca alternifolia) oil solution in the decolonisation of methicillin-resistant Staphylococcus aureus positive wounds and its influence on wound healing.

Authors:  Margaret Edmondson; Nelly Newall; Keryln Carville; Joanna Smith; Thomas V Riley; Christine F Carson
Journal:  Int Wound J       Date:  2011-05-12       Impact factor: 3.315

3.  Tea tree oil-induced transcriptional alterations in Staphylococcus aureus.

Authors:  Jesus A Cuaron; Santosh Dulal; Yang Song; Atul K Singh; Cesar E Montelongo; Wanqin Yu; Vijayaraj Nagarajan; Radheshyam K Jayaswal; Brian J Wilkinson; John E Gustafson
Journal:  Phytother Res       Date:  2012-05-23       Impact factor: 5.878

4.  Does the nose know? An update on MRSA decolonization strategies.

Authors:  C L Abad; M S Pulia; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

5.  Effects of Melaleuca alternifolia (tea tree) essential oil and the major monoterpene component terpinen-4-ol on the development of single- and multistep antibiotic resistance and antimicrobial susceptibility.

Authors:  Katherine A Hammer; Christine F Carson; Thomas V Riley
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

6.  Nasal colonization with methicillin-resistant Staphylococcus aureus: clinical implications and treatment.

Authors:  David Friedel; Michael Climo
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

7.  Adaptation to NaCl Reduces the Susceptibility of Enterococcus faecalis to Melaleuca alternifolia (Tea Tree) Oil.

Authors:  Ee Lin Lim; Katherine Ann Hammer
Journal:  Curr Microbiol       Date:  2015-07-10       Impact factor: 2.188

8.  Treatment of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Kyle J Popovich; Bala Hota; Robert A Weinstein
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

9.  Treatment of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Kyle J Popovich; Bala Hota; Robert A Weinstein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

10.  Essential oils and metal ions as alternative antimicrobial agents: a focus on tea tree oil and silver.

Authors:  Wan-Li Low; Ken Kenward; Stephen T Britland; Mohd Cim Amin; Claire Martin
Journal:  Int Wound J       Date:  2016-05-05       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.